Physician profile
Stephen Ellis
NPI 1801831854
$338.11
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $29.91 · 2021: $12.51 · 2022: $31.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $143.88 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $27.99 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.44 | 2019 | |
| Daiichi Sankyo INC. | $27.24 | 2019 | |
| Octapharma USA, INC. | $24.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.89 | 2022 | |
| Fresenius USA Marketing, INC. | $14.97 | 2019 | |
| Shire North American Group INC | $14.67 | 2019 | |
| Akebia Therapeutics INC | $13.78 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.02 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.